Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NBSE

NeuBase Therapeutics (NBSE) Stock Price, News & Analysis

NeuBase Therapeutics logo

About NeuBase Therapeutics Stock (NASDAQ:NBSE)

Advanced Chart

Key Stats

Today's Range
$0.38
$0.38
50-Day Range
$0.38
$0.38
52-Week Range
$0.36
$4.80
Volume
N/A
Average Volume
N/A
Market Capitalization
$1.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NBSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NBSE Stock News Headlines

Greenlight Capital Q3 2024 Letter
Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
See More Headlines

NBSE Stock Analysis - Frequently Asked Questions

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) announced its quarterly earnings results on Thursday, December, 23rd. The company reported ($4.20) earnings per share for the quarter, topping analysts' consensus estimates of ($4.60) by $0.40.

NeuBase Therapeutics's stock reverse split on Thursday, June 15th 2023.The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuBase Therapeutics investors own include Pfizer (PFE), Energy Transfer (ET), Sio Gene Therapies (SIOX), Avino Silver & Gold Mines (ASM), Actinium Pharmaceuticals (ATNM), Cytokinetics (cytk) and Enbridge (enb).

Company Calendar

Last Earnings
12/23/2021
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NBSE
CIK
1173281
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
3,750,000
Free Float
3,456,000
Market Cap
$1.43 million
Optionable
Not Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:NBSE) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners